Evotec SE has entered a partnership with Hannover Medical School (MHH), a leading German university, to generate a molecular patient database for Sjögren’s syndrome (SjS) and systemic lupus erythematosus (SLE).


 
The strategic partnership aims to achieve a better disease understanding of SjS and SLE by creating a unique longitudinal PanOmics database from the analysis of patient material. Biospecimens from several hundred SjS and SLE patients will be collected by MHH and analyzed on Evotec’s PanOmics platform, which includes genomics, transcriptomics, proteomics, and metabolomics as well as single-cell sequencing technologies. 
 
Together with supplementary pseudonymised patient data, these PanOmics data will feed into Evotec’s translational molecular patient data platform E.MPD, which serves as the central data repository for molecular patient data.


 
For academic research, MHH will receive access to the data generated within the partnership by working with Evotec’s AI-driven analytics software PanHunter. Evotec has the exclusive right to exploit the data commercially with its unique capabilities in the field of data-driven precision medicine. No financial terms were disclosed.


 
Dr. Cord Dohrmann, Chief Scientific Officer of Evotec, said, “We are excited to enter this partnership with MHH and expand Evotec’s E.MPD database into autoimmune diseases. The conventional symptomatic description of many diseases stands in the way of both diagnosis and effective treatment. By leveraging PanOmics data, we are taking a deeper dive into underlying disease mechanisms. A better understanding of molecular disease mechanisms guides the identification of key disease drivers and ultimately supports the identification of new targets and the development of effective medicine.”